Business context and reporting period
Envista Holdings Corporation filed this Form 10-K for the fiscal year ended December 31, 2020. It supplies dental implants, orthodontic products, equipment, consumables and services through Specialty Products & Technologies and Equipment & Consumables. Results were heavily affected by COVID-19 disruptions to dental practices and patient volumes. Comparisons with 2019 also reflect Envista’s 2019 separation from Danaher and the related change from combined to consolidated reporting.
Financial performance
| Metric | 2020 | 2019 |
|---|---|---|
| Sales | $2,282.0 million | $2,751.6 million |
| Core sales change (non-GAAP) | (14.8)% | Flat versus 2018 |
| Gross profit / margin | $1,158.1 million / 50.7% | $1,513.1 million / 55.0% |
| Operating profit / margin | $33.3 million / 1.5% | $277.5 million / 10.1% |
| Net income | $33.3 million | $217.6 million |
| Diluted EPS | $0.20 | $1.60 |
| Operating cash flow | $283.9 million | $397.5 million |
- Annual sales fell 17.1% year over year; lower volume and product mix, primarily from the pandemic, were the main drivers. Foreign exchange reduced sales by 0.3%; discontinued products reduced them by 2.2%.
- Specialty Products & Technologies sales declined 16.8% to $1,117.3 million, with operating margin falling to 6.5% from 17.0%. Equipment & Consumables sales declined 17.3% to $1,164.7 million, with operating margin falling to 3.3% from 7.5%.
- Fourth-quarter sales were $732.3 million versus $720.5 million a year earlier; net income was $108.4 million versus $56.1 million. The filing attributes the full-year downturn principally to COVID-19, while most practices were open by year-end but patient volumes remained below pre-pandemic levels.
- Cash and equivalents were $888.9 million at year-end, up from $211.2 million. Trade receivables were $361.0 million, inventories $266.9 million and current liabilities $1,684.7 million.
- Year-end debt carrying value was $1,794.5 million, including $886.8 million classified as current; contractual debt principal was $1,904.1 million. The company reported $250 million of undrawn revolving capacity at year-end. On February 9, 2021, it repaid $472 million of its Euro Term Loan and substantially reinstated the original credit agreement terms; it reported covenant compliance after the amendment.
Material changes, outlook and notable items
- The effective tax rate was 210.6%, an unusually high rate driven in part by a one-time $59.1 million deferred tax benefit associated primarily with a Swiss tax-basis step-up, alongside the pretax loss. Net income therefore should be considered in light of the tax benefit.
- Restructuring-related charges were $135.4 million in 2020, versus $13.0 million in 2019. The company also disclosed noncash losses associated with exiting part of its treatment-unit business and other restructuring actions.
- Operating cash flow decreased from $397.5 million to $283.9 million, reflecting lower earnings and changes in deferred taxes and accrued liabilities, partly offset by working-capital improvements and higher noncash expenses. Capital expenditures were $47.7 million; the Matricel acquisition used $40.7 million net of cash acquired.
- Management gave no specific numerical revenue or earnings guidance. It cited ongoing investment in implants, orthodontics, infection prevention, digital workflows and emerging markets, alongside cost reductions; a $100 million permanent cost reduction initiative was completed in 2020.
- Management said the timing and extent of recovery remained uncertain because of the pandemic, patient volumes, possible practice closures, economic conditions and supply-chain effects. Other key risks include competition, distributor dependence (Henry Schein represented 11% of sales), regulation, currency exposure, cybersecurity and debt covenants.
- The company had $3.43 billion of goodwill and recorded no goodwill impairment in 2020; the filing notes valuation sensitivity to forecasts, margins, discount rates and market multiples. A Nobel Biocare arbitration was resolved in the fourth quarter within the previously accrued reserve. Management did not expect remaining legal proceedings, net of accruals, to materially affect financial position, though individual-period earnings or cash flows could be affected.
- Envista stated it had no present intention to pay cash dividends. Management and the auditor reported effective internal control over financial reporting, and the auditor issued an unqualified opinion on the financial statements.
Important facts for investors to verify
- Whether dental patient volumes and sales recovered after year-end, and the resulting effect on segment margins and cash generation.
- How much of the 2020 earnings and tax-rate outcome depended on the Swiss tax-basis step-up benefit, and whether further tax adjustments are possible.
- Debt maturity, conversion and liquidity exposure: in particular, the convertible notes’ current classification at year-end, the February 2021 Euro Term Loan repayment, and covenant compliance under reinstated terms.
- Whether restructuring savings offset the charges and excess-capacity costs without impairing product development, customer service or future growth.
- Goodwill valuation assumptions and the potential for impairment if forecasts, margins or market conditions weaken.
- Continuing reliance on Henry Schein and the contribution and risks of international and Greater China markets.